Boehringer Ingelheim achieved strong sales growth in the first half of 2026, as reported on July 15, 2026. This performance was primarily fueled by the strong demand for JARDIANCE® and successful new product launches in the U.S. While specific financial figures for the first half of 2026 were not detailed in the available information, the company had previously reported a 6.3% rise in group net sales to EUR $14.0 billion in the first half of 2025, with JARDIANCE® contributing EUR $4.3 billion and OFEV® EUR $2.0 billion.
The company is making significant strides in its pipeline, particularly with its experimental obesity drug, survodutide (BI 456906). On April 29, 2026, Boehringer Ingelheim announced positive topline results from the Phase III SYNCHRONIZE-1 trial. The trial demonstrated significant weight loss, with participants experiencing an average reduction of up to 16.6% after 76 weeks, compared to 3.2% in the placebo group. Importantly, Survodutide showed a muscle-sparing effect, with lean mass accounting for no more than 10.8% of the total tissue mass change at the highest dose. It also reduced visceral fat by as much as 34% and liver fat by over 60%, showing potential for broader metabolic improvements.
Boehringer Ingelheim is positioning survodutide as a potential first-in-class glucagon/GLP-1 dual agonist, offering a significant advantage in the competitive obesity drug market by preserving muscle while targeting fat loss. The company plans to present the full Phase III data at the American Diabetes Association's 2026 Scientific Sessions in June. This drug is part of a broader metabolic health R&D program, which includes an investigational triple GLP-1, GIP, NPY2 receptor agonist peptide (BI 3034701) entering Phase II in mid-2026, and other oral treatment options. The company's CEO, Shashank Deshpande, highlighted survodutide's potential to address the unmet needs of the more than 1 billion people living with obesity and MASH.
